POLITICS

Trump FDA Chief Marty Makary Resigns After Turmoil

PUBLISHED May 12, 2026, 2:31 PM ET

Read, Watch or Listen

Media Bias Meter

Sources: 9

Center 89%

Right 11%

Sources: 9

Washington: Dr. Marty Makary resigned Tuesday as commissioner of the U.S. Food and Drug Administration, just over a year after taking the post. The resignation came after backlash from health industry executives, anti-abortion activists and other allies of President Donald Trump. Officials have not given an official reason for his departure; a White House official told FOX News the move related to "process at the FDA" and said there was "no bad blood" between Makary and the president. Kyle Diamantis, the FDA's deputy commissioner for Food, will serve as acting commissioner, according to FOX. Makary's tenure lasted just over a year; his resignation ends his leadership role and places Diamantis in the acting post while the agency proceeds under interim leadership.

By Emily Rhodes | JQJO News

Timeline of Events

March 2025: Marty Makary confirmed as FDA commissioner by the Senate.
2025–early 2026: Agency experiences mass layoffs, leadership changes, and policy controversies.
Early May 2026: Reports indicate White House approved a plan to remove Makary.
Tuesday, May 2026: Makary resigns from the FDA; announcement reported by multiple outlets.
Immediately after: Kyle Diamantis (Diamantas) named acting FDA commissioner.

News Intelligence

The FDA oversees food and drug safety, directly impacting your health. Leadership changes can shift priorities and policies. Keep an eye on any new decisions from Acting Commissioner Diamantis.

Media Bias

Articles Published:: 9
Right Leaning:: 1
Left Leaning:: 0
Neutral:: 8

Who Benefited

Certain political allies and advocacy groups critical of Makary, including pro-life organizations and industry stakeholders pressing for regulatory changes, may temporarily regain influence in shaping FDA priorities following his resignation.

Who Impacted

Patients, healthcare providers, FDA career staff, and industry stakeholders face short-term uncertainty in regulatory decision-making and potential delays in drug and device approvals after Makary's departure.

Media Bias